Nodal metastasis in endometrial cancer

Purpose: Besides hysterectomy and bilateral salpingo-oophorectomy, the goal of surgery in early endometrial cancer is to identify extrauterine disease. The purpose of this study was to evaluate disease characteristics and survival of patients found to have nodal metastasis at staging for endometrial cancer. Methods: All patients presenting to our practice from January 1993 to July 2009 with a new diagnosis of early endometrial cancer underwent pelvic and paraaortic lymph node sampling at the time of surgery as permitted by the body mass index. Patient and disease characteristics of patients with nodal metastasis were abstracted by retrospective chart review. Factors contributing to disease-free and overall corrected survival were evaluated. Results: Forty-three patients with an early endometrial cancer were found to have pelvic and/or paraaortic nodal metastasis. Thirty-three percent of patients with nodal metastasis had papillary serous or clear cell cancers. Such tumors were often superficially invasive, yet were more likely to demonstrate lymphovascular space involvement as compared to endometrioid cancers. Furthermore, in a global model of disease-free and overall corrected survival, only tumor histology (endometrioid vs non-endometrioid) was a significant prognostic factor. Excluding clear cell and papillary serous tumors, only tumor grade was a significant prognostic factor in disease-free survival and overall corrected survival in patients with endometrioid adenocarcinomas and nodal involvement. Following adjuvant treatment after surgery, the recurrences were nearly evenly divided between pelvic, paraaortic nodal and distant sites. Only four of 33 (12%) patients treated with adjuvant pelvic radiation experienced a failure in the irradiated field. Furthermore, none of the patients experiencing a paraaortic nodal recurrence received adjuvant radiation to this site. Conclusions: The data suggest a benefit to the use of adjuvant radiation for local control of disease. Furthermore, the use of paclitaxel and carboplatinum chemotherapy also appears a promising adjunct in patients with endometrioid histologies and nodal spread. Papillary serous and clear cell cancers contributed disproportionately to the incidence of nodal metastasis and an adverse prognosis following further adjuvant therapy of patients with nodal disease. Despite taxol/carboplatinum chemotherapy, over half of the patients with non-endometrioid cancers recurred, as opposed to one of 19 endometrioid cancers so treated. The ideal form of adjuvant treatment for such patients remains problematic.

Endometrial cancer; Nodal metastasis; Non-endometrioid endometrial cancers

[1] Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J.: “Cancer statistics, 2009”. CA Cancer J. Clin., 2009, 59, 225.

[2] Morrow C.P., Bundy B.N., Kurman R.J., Creasman W.T., Heller P., Homesley H.D.: “Relationship between surgical-pathologic risk factors and outcome in clinical Stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group Study. Gynecol Oncol., 1991, 40, 55.

[3] Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., Heller P.B.: “Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study”. Cancer, 1987, 60, 2035.

[4] Panici P.B., Basile S., Maneschi F., Lissoni A.A., Signorelli M., Scambia G. et al.: “Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial”. J. Natl. Cancer Inst., 2008, 100, 1707.

[5] The writing committee on behalf of the ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomized study. Lancet, 2009, 373, 125.

[6] Hirahatake K., Hareyama H., Sakuragi N., Nishiya M., Makinoda S., Fujimoto S.: “A clinical and pathologic study on lymph node metastasis in endometrial carcinoma”. J. Surg. Oncol., 1997, 65, 82.

[7] McMeekin D.S., Lashbrook D., Gold M., Scribner D.R., Kamelle S., Tillmanns T.D. et al.: “Nodal distribution and its significance in FIGO Stage IIIC endometrial cancer”. Gynecol. Oncol., 2001, 82, 375.

[8] Cragun J.M., Havrilesky L.J., Calingaert B., Synan I., Secord A.A., Soper J.T. et al.: “Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer”. J. Clin. Oncol., 2005, 23, 3668.

[9] Mariani A., Webb M.J., Keeney G.L., Haddock M.G., Aletti G., Podratz K.C.: “Stage IIIC endometrioid corpus cancer includes distinct subgroups”. Gynecol. Oncol., 2002, 87, 112.

[10] Klopp A.H., Jhingran A., Ramondetta L., Lu K., Gershenson D.M., Eifel P.J.: “Node-positive adenocarcinoma adenocarcinoma of the endometrium: Outcome and patterns of recurrence with and without external beam irradiation”. Gynecol. Oncol., 2009, 115, 6.

[11] Schmid S., I-Cow H., Hu J.M., Sherman A.E., Osann K., Kapp D.S. et al.: “Adjuvant radiation therapy in Stage III node-positive uterine cancer”. Gynecol. Oncol., 2009, 115, 239.

[12] Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Mannel R.S., Fowler J. et al.: “Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Groups Study”. J. Clin. Oncol., 2006, 24, 36.

[13] Hendrickson M., Ross J., Eifel P., Martinez A., Kempson R.: “Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma”. J. Surg. Pathol., 1982, 6, 93.

[14] Sorosky J.I.: “Endometrial cancer”. Obstet. Gynecol., 2008, 111, 436.